Organogenesis Holdings (ORGO) Cash from Financing Activities (2016 - 2026)

Organogenesis Holdings' Cash from Financing Activities history runs 11 years deep, the most recent figure standing at -$20.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 883.12% year-over-year to -$20.2 million; the TTM figure through Mar 2026 stood at -$35.5 million (down 226.0% YoY), while the FY2025 annual figure was -$17.4 million, down 162.81% from the prior year.
• Cash from Financing Activities was -$20.2 million for Q1 2026 at Organogenesis Holdings, down from -$4.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $33.6 million in Q4 2024 to a low of -$20.2 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$1.0 million across 5 years, with a median of -$1.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 5630.77% in 2023, then jumped 1993.58% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$1.9 million in 2022, then gained by 5.23% to -$1.8 million in 2023, then surged by 1993.58% to $33.6 million in 2024, then sank by 114.29% to -$4.8 million in 2025, then plunged by 320.32% to -$20.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$20.2 million (Q1 2026), -$4.8 million (Q4 2025), and -$10.2 million (Q3 2025), per Business Quant data.